NASDAQ:PBYI - Puma Biotechnology Stock Price, Price Target & More

$61.25 -1.10 (-1.76 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$61.25
Today's Range$60.85 - $62.95
52-Week Range$28.35 - $136.90
Volume465,978 shs
Average Volume594,192 shs
Market Capitalization$2.35 billion
P/E Ratio-7.80
Dividend YieldN/A
Beta0.15

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Debt-to-Equity Ratio0.91%
Current Ratio1.82%
Quick Ratio1.79%

Price-To-Earnings

Trailing P/E Ratio-7.80
Forward P/E Ratio-15.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.20 million
Price / Sales88.18
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book43.13

Profitability

EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net MarginsN/A
Return on Equity-278.13%
Return on Assets-158.52%

Miscellaneous

Employees318
Outstanding Shares37,720,000

How to Become a New Pot Stock Millionaire

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) announced its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.98) by $0.27. The biopharmaceutical company had revenue of $21.60 million for the quarter, compared to analyst estimates of $20.83 million. During the same quarter in the prior year, the firm earned ($1.22) earnings per share. View Puma Biotechnology's Earnings History.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Puma Biotechnology.

What price target have analysts set for PBYI?

9 equities research analysts have issued 1 year price objectives for Puma Biotechnology's shares. Their predictions range from $68.00 to $146.00. On average, they expect Puma Biotechnology's share price to reach $103.1111 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:
  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
  • Steven Lo, Chief Commercial Officer (Age 50)
  • Michael P. Miller, Director (Age 60)
  • Jay M. Moyes, Independent Director (Age 63)
  • Adrian M Senderowicz, Independent Director (Age 53)
  • Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
  • Frank E. Zavrl, Independent Director (Age 51)

Has Puma Biotechnology been receiving favorable news coverage?

Media coverage about PBYI stock has been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a daily sentiment score of 0.02 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.28 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $61.25.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $2.35 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (PBYI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Puma Biotechnology (NASDAQ:PBYI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Puma Biotechnology in the last 12 months. Their average twelve-month price target is $103.1111, suggesting that the stock has a possible upside of 68.34%. The high price target for PBYI is $146.00 and the low price target for PBYI is $68.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.782.892.89
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $103.1111$103.1111$130.6667$124.8889
Price Target Upside: 68.34% upside27.53% upside31.65% upside2.87% upside

Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History

Price Target History for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018BarclaysDowngradeOverweight -> Equal Weight$90.00HighView Rating Details
3/9/2018Stifel NicolausSet Price TargetBuy -> Buy$85.00 -> $95.00LowView Rating Details
3/2/2018Credit Suisse GroupSet Price TargetBuy$106.00HighView Rating Details
1/24/2018Bank of AmericaLower Price TargetBuy -> Buy$135.00 -> $115.00HighView Rating Details
1/24/2018CitigroupLower Price TargetBuy -> Buy$164.00 -> $146.00HighView Rating Details
1/24/2018Royal Bank of CanadaLower Price TargetSector Perform$77.00HighView Rating Details
1/24/2018JPMorgan ChaseLower Price TargetOverweight -> Buy$138.00 -> $91.00HighView Rating Details
1/24/2018CowenDowngradeOutperform -> Market Perform$123.00 -> $68.00HighView Rating Details
10/27/2017Leerink SwannBoost Price TargetPositive -> Outperform$140.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Puma Biotechnology (NASDAQ:PBYI) Earnings History and Estimates Chart

Earnings by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Earnings Estimates

2018 EPS Consensus Estimate: ($5.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.87)($1.87)($1.87)
Q2 20181($1.55)($1.55)($1.55)
Q3 20181($1.21)($1.21)($1.21)
Q4 20181($0.95)($0.95)($0.95)

Puma Biotechnology (NASDAQ PBYI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($1.26)N/AView Earnings Details
3/1/2018Q4 2017($1.98)($1.71)$20.83 million$21.60 millionViewListenView Earnings Details
11/9/2017Q3 2017($2.50)($2.07)$3.78 million$6.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
11/9/2016Q3 2016($2.00)($2.02)ViewN/AView Earnings Details
8/9/2016Q2 2016($2.20)($2.05)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.46)($0.49)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.43)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.40)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.74)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Puma Biotechnology (NASDAQ:PBYI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 95.95%
Insider Trading History for Puma Biotechnology (NASDAQ:PBYI)
Insider Trading History for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Alan H AuerbachInsiderSell10,692$92.75$991,683.004,155,931View SEC Filing  
1/22/2018Richard Paul BryceSVPSell1,860$92.75$172,515.0025,379View SEC Filing  
12/1/2017Charles R EylerInsiderSell1,322$105.46$139,418.12View SEC Filing  
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.0042,239View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.0028,239View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.754,170,623View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.0427,246View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.0034,237View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.6428,461View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.484,179,798View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.3229,237View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines

Source:
DateHeadline
Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)Credit Suisse Group Reiterates "Outperform" Rating for Puma Biotechnology (PBYI)
www.americanbankingnews.com - April 17 at 6:29 PM
Puma Biotechnologys (PBYI) Buy Rating Reaffirmed at CitigroupPuma Biotechnology's (PBYI) Buy Rating Reaffirmed at Citigroup
www.americanbankingnews.com - April 17 at 5:27 PM
BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"BidaskClub Upgrades Puma Biotechnology (PBYI) to "Strong-Buy"
www.americanbankingnews.com - April 14 at 9:51 PM
The Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And MoreThe Market In 5 Minutes: Jobless Claims, Walmart-Flipkart, GE And More
www.benzinga.com - April 14 at 4:38 PM
Puma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan ChasePuma Biotechnology (PBYI) Stock Rating Reaffirmed by JPMorgan Chase
www.americanbankingnews.com - April 14 at 3:36 PM
Barclays Downgrades Puma Biotechnology (PBYI) to Equal WeightBarclays Downgrades Puma Biotechnology (PBYI) to Equal Weight
www.americanbankingnews.com - April 12 at 11:15 AM
JPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price TargetJPMorgan Chase Analysts Give Puma Biotechnology (PBYI) a $105.00 Price Target
www.americanbankingnews.com - April 11 at 1:19 PM
Puma Biotechnology (PBYI) Stock Rating Lowered by BidaskClubPuma Biotechnology (PBYI) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM
Puma Biotechnology (PBYI) Cut to "Hold" at BidaskClubPuma Biotechnology (PBYI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 3:25 PM
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 MillionZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million
www.americanbankingnews.com - April 10 at 2:17 AM
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPSZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Announce -$0.75 EPS
www.americanbankingnews.com - April 8 at 9:14 PM
Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"Puma Biotechnology (PBYI) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 8 at 9:07 AM
3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan
seekingalpha.com - April 4 at 9:01 AM
Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin AmericaPuma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
finance.yahoo.com - April 3 at 9:11 AM
Puma's Shares Fall This Year Post a Solid 2017: Here's WhyPuma's Shares Fall This Year Post a Solid 2017: Here's Why
finance.yahoo.com - April 2 at 4:54 PM
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast ...
www.businesswire.com - April 2 at 9:26 AM
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain MetastasesNCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
finance.yahoo.com - April 2 at 9:26 AM
Puma Biotechnology (PBYI) Downgraded to Sell at ValuEnginePuma Biotechnology (PBYI) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM
Puma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse GroupPuma Biotechnology (PBYI) PT Set at $142.00 by Credit Suisse Group
www.americanbankingnews.com - March 28 at 3:48 PM
Puma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from AnalystsPuma Biotechnology Inc (PBYI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 11:54 AM
3 Things In Biotech, March 26: A Focus On European Opinions3 Things In Biotech, March 26: A Focus On European Opinions
seekingalpha.com - March 27 at 9:18 AM
Commit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - NasdaqCommit To Purchase Puma Biotechnology At $50, Earn 11.9% Annualized Using Options - Nasdaq
www.nasdaq.com - March 23 at 4:59 PM
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per SharePuma Biotechnology Inc (PBYI) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - March 22 at 9:14 PM
Stifel Nicolaus Boosts Puma Biotechnology (PBYI) Price Target to $95.00Stifel Nicolaus Boosts Puma Biotechnology (PBYI) Price Target to $95.00
www.americanbankingnews.com - March 9 at 4:23 PM
Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?Does Puma Biotechnology Inc’s (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - March 9 at 9:19 AM
$56.88 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter$56.88 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter
www.americanbankingnews.com - March 7 at 7:45 AM
Puma Biotechnology to Present at Cowen’s Annual Healthcare ConferencePuma Biotechnology to Present at Cowen’s Annual Healthcare Conference
finance.yahoo.com - March 6 at 5:10 PM
Sectoral Asset Management Inc Acquires New Holdings in Puma Biotechnology Inc (PBYI)Sectoral Asset Management Inc Acquires New Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 6 at 2:10 PM
Puma Biotechnology Inc (PBYI) Shares Bought by Teacher Retirement System of TexasPuma Biotechnology Inc (PBYI) Shares Bought by Teacher Retirement System of Texas
www.americanbankingnews.com - March 5 at 3:59 PM
Emory University Reduces Position in Puma Biotechnology Inc (PBYI)Emory University Reduces Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 4 at 2:59 PM
State of Wisconsin Investment Board Buys 6,600 Shares of Puma Biotechnology Inc (PBYI)State of Wisconsin Investment Board Buys 6,600 Shares of Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 4 at 9:31 AM
BidaskClub Lowers Puma Biotechnology (PBYI) to HoldBidaskClub Lowers Puma Biotechnology (PBYI) to Hold
www.americanbankingnews.com - March 3 at 5:48 PM
Puma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse GroupPuma Biotechnology (PBYI) PT Set at $106.00 by Credit Suisse Group
www.americanbankingnews.com - March 3 at 2:16 PM
Puma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from BrokeragesPuma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 3 at 12:05 PM
Why Puma Biotechnology Shares Jumped 15% TodayWhy Puma Biotechnology Shares Jumped 15% Today
finance.yahoo.com - March 3 at 8:55 AM
EAM Investors LLC Decreases Holdings in Puma Biotechnology Inc (PBYI)EAM Investors LLC Decreases Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 3 at 5:40 AM
19,700 Shares in Puma Biotechnology Inc (PBYI) Purchased by Spark Investment Management LLC19,700 Shares in Puma Biotechnology Inc (PBYI) Purchased by Spark Investment Management LLC
www.americanbankingnews.com - March 2 at 8:54 PM
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down - NasdaqPuma (PBYI) Q4 Loss Narrower Than Expected, Shares Down - Nasdaq
www.nasdaq.com - March 2 at 5:33 PM
Puma Biotechnology (PBYI) Price Target Cut to $90.00Puma Biotechnology (PBYI) Price Target Cut to $90.00
www.americanbankingnews.com - March 2 at 3:12 PM
Puma Biotechnology (PBYI) Issues  Earnings ResultsPuma Biotechnology (PBYI) Issues Earnings Results
www.americanbankingnews.com - March 2 at 10:39 AM
Stock Traders Purchase Large Volume of Put Options on Puma Biotechnology (PBYI)Stock Traders Purchase Large Volume of Put Options on Puma Biotechnology (PBYI)
www.americanbankingnews.com - March 2 at 7:30 AM
Swiss National Bank Has $5.02 Million Position in Puma Biotechnology Inc (PBYI)Swiss National Bank Has $5.02 Million Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 1 at 5:42 PM
Puma Biotechnology, Inc. to Host Earnings CallPuma Biotechnology, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 5:17 PM
Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial ResultsPuma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 5:17 PM
Carillon Tower Advisers Inc. Invests $20.54 Million in Puma Biotechnology Inc (PBYI)Carillon Tower Advisers Inc. Invests $20.54 Million in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - March 1 at 5:38 AM
Puma Biotechnology Inc (PBYI) Position Lifted by Wells Fargo & Company MNPuma Biotechnology Inc (PBYI) Position Lifted by Wells Fargo & Company MN
www.americanbankingnews.com - February 28 at 5:24 PM
California Public Employees Retirement System Has $11.22 Million Position in Puma Biotechnology Inc (PBYI)California Public Employees Retirement System Has $11.22 Million Position in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - February 28 at 5:24 AM
Puma Biotechnology Inc (PBYI) Shares Sold by Ascend Capital LLCPuma Biotechnology Inc (PBYI) Shares Sold by Ascend Capital LLC
www.americanbankingnews.com - February 28 at 4:44 AM
Blog Exposure - CHMP Recommended Against Approval of Puma Biotechs Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast CancerBlog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer
finance.yahoo.com - February 27 at 8:59 AM
Schwab Charles Investment Management Inc. Has $13.86 Million Holdings in Puma Biotechnology Inc (PBYI)Schwab Charles Investment Management Inc. Has $13.86 Million Holdings in Puma Biotechnology Inc (PBYI)
www.americanbankingnews.com - February 27 at 5:50 AM

SEC Filings

Puma Biotechnology (NASDAQ:PBYI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Puma Biotechnology (NASDAQ PBYI) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.